Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.36 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.35 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16339854 | 0.89 | HDAC3 (0.39) | GPR6 | |
| SCHEMBL16339438 | 0.86 | HDAC3 (0.37) | GPR6 | |
| SCHEMBL16339370 | 0.85 | HDAC1 (0.42) | HDAC1BRPF1BRD4HTTMCHR1 | |
| SCHEMBL16339295 | 0.85 | HDAC1 (0.42) | HDAC1CTNNB1TCF7L2GPR6 | |
| SCHEMBL16339612 | 0.84 | HDAC1 (0.60) | HDAC1CTNNB1TCF7L2HTT | |
| SCHEMBL16339342 | 0.84 | USP30 (0.39) | HDAC1BRPF1BRD4CTNNB1TCF7L2 | |
| SCHEMBL16339556 | 0.84 | USP30 (0.39) | HDAC1BRPF1BRD4CTNNB1TCF7L2 | |
| SCHEMBL16339855 | 0.84 | USP28 (0.40) | HDAC1BRPF1BRD4CTNNB1TCF7L2 | |
| SCHEMBL16339343 | 0.84 | USP30 (0.39) | HDAC1BRPF1BRD4CTNNB1TCF7L2 | |
| Hydrochloric Acid SCHEMBL17765378 | 0.83 | HDAC1 (0.59) | HDAC1CTNNB1TCF7L2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | claimed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | claimed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | claimed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | claimed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | claimed |
| WO-2021007378-A1 | COMPOUNDS FOR USE IN TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | HDAC1 453/4885BRPF1 1152/4885BRD4 2013/4885 |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | HDAC1 453/4885BRPF1 1152/4885BRD4 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.